Insider trading of David Altshuler, a EVP, Global Research and CSO at VRTX Vertex Pharmaceuticals Incorporated
Most recently David Altshuler sold 6,403 shares worth $965,700.46 on 12 February 2018.
|Shares||Price per share||Total price||Shares after||Source|
|2018-02-12||VRTX||David Altshuler||EVP, Global Research and CSO||Sale||6,403||$150.82||$965,700||69,999|
|2018-02-02||VRTX||David Altshuler||EVP, Global Research and CSO||Option exercise||1,796||$91.05||$163,526||51,557|
|2018-01-22||VRTX||David Altshuler||EVP, Global Research and CSO||Option exercise||1,796||$91.05||$163,526||51,557|
|2018-01-16||VRTX||David Altshuler||EVP, Global Research and CSO||Sale||56,250||$156.99||$8,830,688||49,761|
|2017-11-15||VRTX||David Altshuler||EVP, Global Research and CSO||Sale||306||$149.12||$45,631||106,011|
|2017-08-31||VRTX||David Altshuler||EVP, Global Research and CSO||Option exercise||1,796||$91.05||$163,526||107,807|
|2017-07-19||VRTX||David Altshuler||EVP, Global Research and CSO||Option exercise||28,979||$84.49||$2,448,436||134,990|
|2017-06-05||VRTX||David Altshuler||EVP, Global Research and CSO||Option exercise||7,500||$72.14||$541,050||113,511|
|2017-05-15||VRTX||David Altshuler||EVP, Global Research and CSO||Sale||181||$114.37||$20,701||106,011|
|2017-04-28||VRTX||David Altshuler||EVP, Global Research and CSO||Option exercise||7,500||$63.14||$473,550||113,511|
|2017-02-13||VRTX||David Altshuler||EVP, Global Research and CSO||Sale||6,403||$87.68||$561,415||106,011|
Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; CRISPR Therapeutics AG; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston 02210, United States